Join Trial Testing New Drug for Improving A1C in Type 1 Diabetes
This study is recruiting participants to test the effectiveness of CT-868, a new investigational medication for blood sugar management being tested in people with type 1 diabetes and obesity.
Trial status: Recruiting
Clinical Trials Identifier: NCT06062069
Trial Name: A Study of CT-868 in Type 1 Diabetes Mellitus
Diabetes Type: Adults with type 1 diabetes and with obesity or overweight
Trial Sponsor: Carmot Therapeutics, Inc.
Why is this study important?
This study is investigating the effects of CT-868, a once-daily injectable GLP-1/GIP receptor agonist, in people with type 1 diabetes and obesity or overweight. If successful, CT-868 could be considered an adjunct or supplementary treatment to insulin for managing type 1 diabetes.
How does the trial work?
Participants will be randomly assigned to either the active treatment or placebo group. Those assigned to the treatment group will be split into one of three dosing groups (low, medium, or high) and receive a daily injection of CT-868 via a pre-filled pen injector device for 16 weeks. The placebo group will also receive daily injections that contain a placebo designed to match the appearance of the drug CT-868.
Participants will also receive guidance on managing their diabetes, including monitoring blood glucose levels, as well as diet and exercise recommendations during the study. All participants will wear a continuous glucose monitor (CGM) device throughout the trial in addition to continuing with their standard diabetes care regimen of using an insulin pump or multiple daily injections.
To determine the safety and effectiveness of CT-868, researchers will measure participants’ A1C levels at baseline and again at 16 weeks. They will also assess other outcome measures such as change in body weight and time in range.
Are you interested in participating?
You may be eligible to participate if you are 18 years of age or older and have:
- Been diagnosed with type 1 diabetes for at least one year before the screening visit
- A BMI of 27 or higher
- An A1C between 7-10%
People with type 2 diabetes are not eligible for this study. This trial is currently recruiting in multiple locations across the U.S. See a full list of inclusion/exclusion criteria here.
Learn more about type 1 diabetes treatments and trials here: